Ustekinumab for children and adolescents with inflammatory bowel disease at a tertiary children's hospital in Japan

Abstract

Ustekinumab may be an effective and safe treatment option for pediatric and adolescent Crohn's disease and Crohn's disease-like inflammatory bowel disease patients having nonresponse or adverse reactions to anti-tumor necrosis factor agents.